PatrickMMoriartyMD

PubMed

• 135 citations
  Optimizing Cholesterol Treatment in Patients With Muscle Complaints.
  Robert S. Rosenson, Steven K. Baker, Maciej Banach, Kenneth M. Borow, Lynne T. Braun
  Journal of the American College of Cardiology. 2017-09-05
• 245 citations
  Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel
  Maciej Banach, Manfredi Rizzo, Peter P. Toth, Michel Farnier, Michael H. Davidson
  Archives of Medical Science. 2015-03-14
• 78 citations
  Interleukin-1β Induces Calcium Transients and Enhances Basal and Store Operated Calcium Entry in Human Myometrial Smooth Muscle
  Rachel M. Tribe, Patrick Moriarty, Annette Dalrymple, Abdul A. Hassoni, Lucilla Poston
  Biology of Reproduction. 2003-05-01

Journal Articles

• Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Sever...  
  Raul D Santos, Samuel S Gidding, Robert A Hegele, Marina A Cuchel, Philip J Barter, Gerald F Watts, Seth J Baum, Alberico L Catapano, M John Chapman, Joep C Defesche, ..., Lancet Diabetes-Endocrinol, 1/1/2016
• JCL Roundtable: PCSK9 Inhibitors in Clinical Practice  
  Brown WV, Moriarty PM, McKenney JM, Journal of Clinical Lipidology, 1/1/2016
• JCL Roundtable: Should We Treat Elevations in Lp(a)?  
  Brown WV, Moriarty PM, Remaley AT, Tsimikas S, Journal of Clinical Lipidology, 1/1/2016
• Statin Intolerance and Vitamin D Supplementation: Sunny, but a Few Clouds Remain  
  Backes JM, Ruisinger JF, Brian BJ, Moriarty PM, North American Journal of Medical Sciences, 1/1/2015
• Statin intolerance – an attempt at a unified definition  
  Maciej Banach, Manfredi Rizzo, Peter P. Toth, Michel Farnier, Michael H. Davidson, Khalid Al-Rasadi, Wilbert S. Aronow, Vasilis Athyros, Dragan M. Djuric, Marat V. Ezh..., Archives of Medical Science, 1/1/2015
• Initial results from the cascade-fh registry: cascade screening for awareness and detection of familial hypercholesterolemia  
  Emily C. O'Brien, Emil M. deGoma, Patrick M. Moriarty et al, J Am Coll Cardiol, 1/1/2015
• Lipoprotein Apheresis  
  Moriarty PM, Hemphill L, Cardiol Clin, 1/1/2015
• National Heart, Lung and Blood Institute State of the Science Symposium in Therapeutic Apheresis – Therapeutic Apheresis in Cardiovascular Disease  
  Winters JL, Cooper LT, Ratcliffe NR, Wu Y, Moriarty PM, Journal of Clinical Apheresis, 1/1/2015
• Long-Term Follow Up of Bi-Weekly Lipoprotein Apheresis in A patient with Elevated Lipoprotein-(a) Shows Regression in Carotid Intima-Media Thickness  
  Anabtawi A, Patel P, Deuschele L, Moriarty PM, Journal of Clinical Lipidology, 1/1/2015
• Lipoprotein Apheresis: Present and Future Uses  
  Moriarty PM, Current Opinion Lipidology, 1/1/2015
• Analysis of vitamin D levels in patients with and without statin associated myalgia – A systematic review and meta-analysis of 7 studies with 2420 patients  
  Michalska-Kasiczak M, Sahebkar A, Mikhailidis DP, Rysz J, Muntner P, Toth PP, Jones SR, Rizzo M, Hovingh GK, Farnier M, Moriarty PM, Bittner VA, Lip GYH, Banach M, International Journal of Cardiology, 1/1/2015
• Hypertriglyceridemia unresponsive to multiple treatments  
  Backes JM, Dayspring TD, Hoefer DM, Moriarty PM, BMJ Case Reports, 1/1/2015
• Identifying pseudohypertriglyceridemia in clinical practice  
  Backes JM, Dayspring TD, Hoefner DM, Contois JH, McConnell JP, Moriarty PM, Clinical Lipidology, 1/1/2014
• Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: Design and rationale of ODYSSEY ALTERNATIVE, a randomized Phase 3 trial  
  Journal of Clinical Lipidology, 1/1/2014
• First on-line survey of an international multidisciplinary working group (MightyMedic) on current practice in diagnosis, therapy and follow-up of dyslipidemias  
  Stefanutti C, D’Alessandri G, Petta A , Harada-Shiba M, Julius U, Soran H, Moriarty PM, Romeo S, Jaeger BR and the MightyMedic (Multidisciplinary International Group f..., Atherosclerosis Supplement Journal, 1/1/2014
• Effects of Xuezhikang in patients with dyslipidemia: A multicenter, randomized, placebo-controlled study  
  PM. Moriarty, EM. Roth, A. Karns, P.Ye, S. Zhao, Y. Liao, DM. Capuzzi, HE. Bays, F. Zhang, S. Liu, AJ. Reichman, OA. Brusco, G. Lu, S. Lerman, Z. Duan, S. Guo, PL. Liu..., Journal of Clinical Lipidology, 1/1/2014
• Analysis of vitamin d levels in patients with and without statin-associated myalgia – a systematic review And meta-analysis of 7 studies with 2420 patients  
  Michalska-Kasiczak M, Sahebkar, Mikhailidis DP, Rysz J, Muntner P, Toth PP, Jones SR, Rizzo M, Hovingh GK, Farnier M, Moriarty PM, Bittner VA, Lip G, Banach M, International Journal of Cardiology, 1/1/2014
• The Effects of Mipomersen, a Second-Generation Antisense Oligonucleotide, on Atherogenic (apoB-containing) lipoproteins in the Treatment of Homozygous Familial Hyperch...  
  McGowan MP, Moriarty PM, Backes JM, Clinical Lipidology, 1/1/2014
• Evaluating the Effects of Prescription Fish Oil, Supplemental Fish Oil and a Krill Oil Blend on Serum Lipids/Lipoproteins and the Omega-3 Index: a Pilot Study  
  Backes JM, Ruisinger JF, Harris KA, Gibson CA, Harris WS, Moriarty PM, Journal of Glycomics and Lipidomics, 1/1/2014
• Statins and Almonds to Lower Lipoproteins (the STALL Study)  
  Ruisinger J, Gibson C, Backes J, Smith B, Sullivan D, Moriarty PM, Kris-Etherton P, Journal of Clinical Lipidology, 1/1/2014
• National Heart, Lung, and Blood Institute State of the Science Symposium in Therapeutic Apheresis – Therapeutic Apheresis in Cardiovascular Disease  
  Jeffrey L. Winters, Leslie T. Cooper, Nora R. Ratcliffe, Yanyun Wu, Patrick M. Moriarty, Journal of Clinical Apheresis, 1/1/2014
• Red yeast rice extract shows equivalency to statins  
  E.M. Roth, P. Moriarty, S. Li et al, Circulation, 1/1/2013
• Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolemia: 2-year interim results of an open-label extension  
  R. Santos, B. Duell, C. East, J. Guyton, P. Moriarty, W. Chin, R. Mittleman, European Heart Journal, 1/1/2013
• Utility of the Canadian Treatment Optimization Recommendations (TOR) in MS care  
  Grand'Maison F, Bhan V, Freedman MS, Myles ML, Patry DG, Selchen DH, Moriarty P, Traboulsee AL, Can J Neurol Sci, 1/1/2013
• A Hungarian rhapsody in lipids  
  Moriarty PM, Journal of Clinical Lipidology, 1/1/2013
• Join now to see all

Books/Book Chapters

• Clinical Lipidology: A Companion to Braunwald's Heart Disease 
  Chapter: Special Patient Populations: Familial Hypercholesterolemia and Other Severe Hypercholesterolemias 
  Page 440.0 - 453.0Moriarty PM, Santos RDSaunders/ElsevierEdition 2nd,2015
• Cardiology Clinics: Lipidology 
  Chapter: Lipoprotein Apheresis 
  Page 197.0 - 208.0Moriarty PM, Hemphill Linda2015
• Clinical Challenges in Lipid Disorders 
  Chapter: What is familial hypercholesterolemia and how should it be treated? 
  Moriarty PM, Backes J, Gibson CAClinical Publishing, Oxford
• Therapeutic Lipidology (Contemporary Cardiology) 
  Chapter: Familial Hypercholesterolemia and Lipid Apheresis 
  Moriarty PM, Gibson CA, Flechsenhar KHumana Press Inc
• Clinical Lipidology: A Companion to Braunwald's Heart Disease 
  Chapter: LDL-apheresis 
  Moriarty PMSaunders/Elsevier
• Join now to see all

Abstracts/Posters

• Impact Of Lipoprotein Apheresis on Serum Myeloperoxidase Levels in Patients with Familial Hypercholesterolemia
  Sehar N, Moriarty, PM, European Atherosclerosis Society, Glasgow, Scotland, 1/1/2015
• Long Term Follow up of Bi-Weekly Lipoprotein Apheresis in A patient with Elevated Lipoprotein-(a) Shows Regression in Carotid Intima-Media Thickness
  Abeer Anabtawi, Priyanka Patel, Lisa Deuschele, Patrick Moriarty, National Lipid Association, Chicago, Illinois, 1/1/2015
• Resolution of recurrent postoperative pericarditis after lipid apheresis: a case report
  Moriarty PM, Heckerson N, Journal of Clinical Lipidology, 1/1/2012
• Reduction of Inflammatory HDL Following LDL-apheresis Treatment
  Moriarty P, Opole IO, Kumar A, Belmont JM, American Heart Association, ISA06 XIV International Symposium on Atherosclerosis, Rome , Italy, 1/1/2006
• Blood Viscosity: A Marker of Asymptomatic Vascular Disease in Children
  Moriarty PM, AHA 46th Annual conference on Cardiovascular Disease Epidemiology and Prevention in association with the Council of Nutrition, Physical Activity, and Metabolism, Phoenix, Arizona, 1/1/2006
• Atherosclerosis and Rheology: which comes first the chicken or the egg?
  Moriarty PM, 13th Conference of the European Society for Clinical Hemorheology (E.S.C.H.)/Hemorheopheresis session of the 5th International Society for Apheresis, Siena, Italy, 2005; Rostock/Warnemuende, Germany, 2005, 1/1/2005
• LDL Apheresis and Its Effect on Whole Blood Viscosity
  Moriarty PM, Gibson, CA, Kensey, KR, Hogenauer, WN, Journal of Clinical Apheresis, American Society for Apheresis, 1/1/2003
• Dyslipidemia and cardiovascular disease: Significance of treatment
  Moriarty PM, 5th International Symposium on Multiple Risk Factors in Cardiovascular Disease: Global Assessment and Intervention, Venice, Italy, 1/1/1999
• Relative risk reduction vs. number needed to treat as measures of lipid trials results
  Moriarty PM, XIth International Symposium on Atherosclerosis, Paris, 1/1/1998
• Eosinophil fasciitis as a graph vs. host disease from an autologous bone marrow transplant
  Moriarty PM, Kansas Association of Internal Medicine, Kansas City, KS, 1/1/1993
• Neutropenia induced from chronic metoclopramide
  Moriarty PM, Kansas Association of Internal Medicine, Kansas City, KS, 1/1/1992
• Evaluating vitamin D dosing in obese patients with low vitamin D levels
  Schuessler B, Ruisinger JF, Moriarty PM, Backes JM, The Midwest Pharmacy Residents Conference, Omaha, NE, 1/10/2012
• Effect of Low Density Lipoprotein Apheresis on Plasma Levels of Apoliprotein E4
  Moriarty PM, Luyendyk JP, Gibson CA, Backes JM, International Academy of Cardiology 15th World Congress on Heart Disease Annual Scientific Sessions, Vancouver, BC, Canada, 1/26/2010
• Aggressive treatment of cardiovascular risk factors results in the reduction of atherosclerosis growth as measured by carotid intima media thickness: experience from a...
  D. M. Eldringhoff, J.M. Backes, J.F. Ruisinger, J.S. Dutton, B.J. Barnes, J.M. Belmont, P.M. Moriarty, International Academy of Cardiology, 15th World Congress on Heart Disease Annual Scientific Sessions, Vancouver, BC, Canada, 1/26/2010
• Acute Reduction of Lipoprotein(a) After Low-Density Lipoprotein Apheresis May Improve Symptoms of Angina
  Bulchandani D, Moriarty PM, International Academy of Cardiology 15th World Congress on Heart Disease Annual Scientific Sessions, Vancouver, BC, Canada, 1/27/2010
• LDL-apheresis for Prevention of Recurrent Hypertriglyceridemia-Induced Acute Pancreatitis, A Case Report
  Saad AF, Moriarty PM, National Lipid Association Scientific Session, New York, New York, 1/20/2011
• The Effect of Aggressive Cardiovascular Treatment on the Progression of Carotid Intima-Media Thickness: Experience of an Atherosclerosis Prevention Center
  Moriarty PM, Gibson CA, Backes JM, Eldringhoff DM, Powell S, Ruisinger JF, 79th European Atherosclerosis Society Congress, Gothenburg, Sweden, 1/26/2011
• LDL-apheresis for Prevention of Recurrent Hypertriglyceridemia-Induced Acute Pancreatitis, A Case Report
  Saad AF, Moriarty PM, 79th European Atherosclerosis Society Congress, Gothenburg, Sweden, 1/26/2011
• Beyond Statins: LDL Management in the Challenging Patient
  Moriarty PM, ACC 61st Annual Scientific Session ACC-i2 with TCT, Chicago, Illinois, 1/24/2012
• Adult Relapsing Focal Segmental Glomerulosclerosis (FSGS) Maintained In Partial Remission Following Lipoprotein Apheresis: Case Study
  A. Haikal, N. Sehar, L. Denney, P. Moriarty, European Atherosclerosis Society, 1/29/2016
• The Effect Of Aggressive Cardiovascular Treatment On The Progression Of Carotid Intima-Media Thickness: Experience Of An Atherosclerosis Prevention Center
  Wilson, M, Gibson C, Powell S, Eldringhoff D, Backes J, Moriarty PM, Scottsdale, AZ, 1/1./2012
• Apple-pectin and its ability to reduce niacin-induced flushing
  Moriarty PM, Backes JM, Ruisinger JF, Schmelzle K, Dutton JA, He W, The European Atherosclerosis Society Congress, Milan, Italy, 1/26/2012
• EECP Therapy for Patients with Mild Cognitive Impairment
  P.M. Moriarty, A.H. Badawi, RJ. Lepping, B. Nolte, SL. Tye, M. Bishara, J. Burns, WM. Brooks, International Conference on Heart and Brain, 1/25/2016
• A Familial Hypercholesterolemic Patient Treated with Heparin-Induced Extracorporeal LDL Precipitation (HELP)
  Moriarty, PM, Gibson, CA, 1/8./2002
• Elevated Lipoprotein(A) And Ischemic Strokes- A Case Report
  P. Moriarty, N. Sehar, L. Denney, F. Perez-Marques, A. Panchal, P. Luna, European Atherosclerosis Society, 1/29/2016
• Join now to see all

Lectures

• Diagnosis and treatment of abnormal cholesterolemia in the diabetic patient including the metabolic syndrome patient 
  KU Med - 1/1/2005
• Diabetic Lipid Management: How low should we go? 
  Kansas City, MO - 1/1/2005
• Atherosclerosis and its association with hemorheology 
  St. Luke’s Hospital, Kansas City, MO - 1/1/2005
• Novel CV Risk Factors 
  Kansas City, Missouri - 1/1/2005
• LDL Apheresis and the treatment of Familial Hypercholesterolemia (FH) 
  Chicago, Illinois - 1/1/2005
• Treatment of Dyslipidemia and Atherosclerosis 
  Carondelet Heart Institute, Kansas City, MO - 1/24/2015
• FH and Present Day Management: Why This Disease is Vital to Treat 
  Las Vegas, NV - 1/30/2013
• Statin Intolerance: Therapeutic Options 
  Vienna, Austria - 1/6./2014
• Lipid Apheresis for elevated Lp(a) 
  Vienna, Austria - 1/6./2014
• Efficacy And Safety of the Proprotein Convertase Subtilisin/kexin Type 9 Monoclonal Antibody, Alirocumab, versus Ezetimibe, in Patients With Statin Intolerance as Defi... 
  Chicago, Illinois - 1/17/2014
• Advanced Approaches for Optimizing Outcomes in the Severe FH Patient 
  Boston, Massachusetts - 1/23/2014
• Decision Making in Medication Based Prevention of Coronary Artery Disease in the Era of Multiple Guidelines 
  Kansas City, KS - 1/4./2014
• The Present Treatment of Elevated Lp(a) and CVD Prevention: Lipid Apheresis 
  Rome, Italy - 1/6./2014
• Lp(a) as a target 
  Orlando, Florida - 1/2./2014
• Effect of Acute Cholesterol Lowering on Lipoprotein 
  Dresden, Germany - 1/14/2014
• Lipoprotein(a) and the Risk of Cardiovascular Disease: Pathophysiology, diagnosis, and treatment 
  Hangzhou, China - 1/10/2013
• Rheological Implications of Apheresis in FH 
  Las Vegas, NV - 1/30/2013
• Inflammatory and apoE4-bound HDL pre and post apheresis 
  Dresden, Germany - 1/19/2016
• PCSK9 Inhibitors for Patients with Statin Intolerance (Alternative Trial), FH Patients Receiving Lipoprotein Apheresis (Escape Trial) 
  1/15/2015
• Rheological Improvement In Lipid Apheresis – More Than A Pleiotropic Effect? 
  Cancun, Mexico - 1/15/2015
• Evaluating Residual Risk and Long Term Management of the Young CHD Patient 
  Chicago, Illinois - 1/14/2015
• Statin Intolerance and PCSK9 Inhibitors 
  Kansas City, Kansas - 1/22/2015
• FH Cascade Registry 
  Pasadena, California - 1/25/2015
• Lipid Apheresis and Statin Therapy 
  Kansas City, KS - 1/6./2015
• Special Considerations in Familial Hypercholesterolemia 
  Boston, Massachusetts - 1/22/2015
• Join now to see all

Other

• Expert Roundtable: Familial Hypercholesterolemia 
  Underberg James, Brinton, Eliot, McGowan, Mary, Moriarty PM, The Medical Roundtable: Cardiovascular Edition
  1/1/2012
• Lipoprotein-Associate Phospholipase A2: Effects of Low Density Lipoprotein Apheresis 
  Moriarty PM, ather.org
  1/1/2005
• Patient Presents to the Atherosclerosis and Lipoprotein Apheresis Clinic Unable to Reach LDL-C Goal Despite Lipid-Modifying Agents 
  Moriarty PM, http://www.acc.org
  http://education.acc.org/Lifelong-Learning-and-MOC/Certified-Learning/Case-Vignettes/2015/Prevention/Prev_FH_HoFH_Moriarty.aspx
  1/26/2015
• Homozygous Familial Hypercholesterolemia 
  Gidding SG, Moriarty PM, Raghuveer G, http://www.acc.org
  http://education.acc.org/Lifelong-Learning-and-MOC/Certified-Learning/EAO/2015/FH-and-HoFH-Panel-Discussion.aspx
  1/26/2015
• Reducing Lp(a) Prevents Major Coronary Events. Prevention of Major Adverse Coronary Events Through Lipid Apheresis in Patients with High Lipoprotein (a) Levels and Pro... 
  Jaeger BR et al, Nature Reviews: Cardiology
• Join now to see all